Abstract:<p>Dysregulation of histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been implicated in the pathogenesis of many cancers. However, the role of EZH2 in peritoneal fibrosis remains unknown. We investigated EZH2 expression in peritoneal dialysis (PD) patients and assessed its role in peritoneal fibrosis in cultured human peritoneal mesothelial cells (HPMCs) and murine models of peritoneal fibrosis induced by chlorhexidine gluconate (CG) or high glucose peritoneal dialysis fluid (PDF) by using 3‐deazaneplanocin A (3‐DZNeP), and EZH2 conditional knockout mice. An abundance of EZH2 was detected in the peritoneum of patients with PD associated peritonitis and the dialysis effluent of long‐term PD patients, which was positively correlated with expression of transforming growth factor‐β1 (TGF‐β1), vascular endothelial growth factor, and interleukin‐6. EZH2 was found highly expressed in the peritoneum of mice following injury by CG or PDF. In both mouse models, treatment with 3‐DZNeP attenuated peritoneal fibrosis and inhibited activation of several pro‐fibrotic signaling pathways, including TGF‐β1/Smad3, Notch1, epidermal growth factor receptor and Src. EZH2 inhibition also inhibited STAT3 and nuclear factor‐κB phosphorylation, and reduced lymphocyte and macrophage infiltration and angiogenesis in the injured peritoneum. 3‐DZNeP effectively improved high glucose PDF‐associated peritoneal dysfunction by decreasing the dialysate‐to‐plasma (D/P) ratio of BUN and increasing the ratio of dialysate glucose at 2 h after PDF injection to initial dialysate glucose. Moreover, delayed administration of 3‐DZNeP inhibited peritoneal fibrosis progression, reversed established peritoneal fibrosis and reduced expression of tissue inhibitor of metalloproteinase 2 (TIMP2), and matrix metalloproteinase‐2 and ‐9. Finally, EZH2‐KO mice exhibited less peritoneal fibrosis than EZH2‐WT mice. In HPMCs, treatment with EZH2 siRNA or 3‐DZNeP suppressed TGF‐β1‐induced upregulation of α‐SMA and Collagen I and preserved E‐cadherin. These results indicate that EZH2 is a key epigenetic regulator that promotes peritoneal fibrosis. Targeting EZH2 may have the potential to prevent and treat peritoneal fibrosis.</p><p>This article is protected by copyright. All rights reserved.</p>

PI3K/Akt signaling regulates epithelial-mesenchymal transition of peritoneal mesothelial cells in peritoneal dialysis

AKT Regulation of Mesothelial-to-mesenchymal Transition in Peritoneal Dialysis is Modulated by Smurf2 and Deubiquitinating Enzyme USP4

The role of PI3K/Akt signal pathway in epithelia-mesenchymal transition of human peritoneal mesothelial cell induced by transforming growth factor β1

Effects of Short Hairpin RNAs on TGF-β1 Expression and Ultrastructure in HPMCs Induced by Peritoneal Dialysis Solution

Role of miR-129-5p in regulation of epithelial-mesenchymal transition of peritoneal mesothelial cells

RhoA/Rho-kinase Triggers Epithelial-Mesenchymal Transition in Mesothelial Cells and Contributes to the Pathogenesis of Dialysis-Related Peritoneal Fibrosis

Aberrant Wnt/Beta-Catenin Pathway Activation in Dialysate-Induced Peritoneal Fibrosis

IL-6 Trans-Signaling Drives a STAT3-dependent Pathway That Leads to Structural Alterations of the Peritoneal Membrane.

MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis

Transforming Growth Factor Β1 Induces Epithelial–mesenchymal Transition by Activating the Jnk–SMAD3 Pathway in Rat Peritoneal Mesothelial Cells

Inhibition of PI3K/AKT/mTOR Signalling Pathway Activates Autophagy and Suppresses Peritoneal Fibrosis in the Process of Peritoneal Dialysis

Activation of AMPK-PGC-1α pathway ameliorates peritoneal dialysis related peritoneal fibrosis in mice by enhancing mitochondrial biogenesis

Extracellular vesicle-packaged ILK from mesothelial cells promotes fibroblast activation in peritoneal fibrosis

MiR-200a Negatively Regulates TGF-β1-induced Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells by Targeting ZEB1/2 Expression

Epithelial-mesenchymal Transition of Human Peritoneal Mesothelial Cells Isolated from Effluent Fluid in Dialysis

Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis

Endothelin-1 triggers human peritoneal mesothelial cells' proliferation via ERK1/2-Ets-1 signaling pathway and contributes to endothelial cell angiogenesis.

Small Interfering RNA Targeting ILK Inhibits EMT in Human Peritoneal Mesothelial Cells Through Phosphorylation of GSK‑3β.

MicroRNA-302c Modulates Peritoneal Dialysis-Associated Fibrosis by Targeting Connective Tissue Growth Factor

Autophagy Promotes Fibrosis and Apoptosis in the Peritoneum During Long-Term Peritoneal Dialysis

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.